Osteo Arthritis Knee
Conditions
Keywords
osteoarthritis, physical function, nutrition
Brief summary
The overall goal of this pilot randomized trial is to obtain necessary prerequisite data to conduct a randomized controlled intervention to test the effect of vitamin K supplementation on knee osteoarthritis progression and related functional decline. To address critical parameters required to design this larger RCT, we will conduct a double-blind, 2-armed, parallel-group intervention study, with a placebo run-in, in which 50 adults with mild to moderate knee OA and low baseline vitamin K status will be randomly assigned to 1 mg phylloquinone/day or matching placebo, and treated for 6 months. Specifically, we will: (1) compare the effects of 1 mg/day phylloquinone vs. placebo on the non-functional circulating form of MGP; (2) estimate rates of recruitment and retention, follow-up rates and reasons for loss to follow-up, response rates to questionnaires, adherence/compliance rates, and potential for site differences; and (3) determine the responsiveness of the Osteoarthritis Research Society International (OARSI)-recommended performance-based tests of physical function in adults with low vitamin K status and mild to moderate knee osteoarthritis. We will also obtain preliminary data on the distribution of MGP genotype at two clinical sites for effect size generation. As of February 2025, based on attrition rate below what was initially expected, we revised our planned enrollment from 50 to 35, to achieve the original goal of 30 completers. This was approved by the study sponsor.
Interventions
DIETARY_SUPPLEMENTVitamin K
1 mg/day phylloquinone (vitamin K1)
DIETARY_SUPPLEMENTPlacebo
Placebo capsule once daily
Sponsors
University of North Carolina, Chapel Hill
Tufts Medical Center
University of Massachusetts, Worcester
Tufts University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ 50 years * Male or post-menopausal female (no menses in the last year) * Plasma phylloquinone \<1.0 nmol/L * Chronic knee discomfort based on affirmative response to the question During the past 12 months, have you had pain, aching, or stiffness in or around your knee(s) on most days for at least one month? * Kellgren-Lawrence (KL) grade 2-3 in at least one knee * Ability to understand study procedures and to comply with them for the entire length of the study * Ability to answer questions by phone * Ability to swallow capsules
Exclusion criteria
* KL grade 4 in at least one knee * Inability to walk * Cognitive impairment (based on a Montreal Cognitive Assessment Test score ≤ 17) * Widespread pain * Malabsorption disorders (e.g. advance liver disease, stage 4 or 5 chronic renal disease, Crohn's disease, celiac sprue) * Serious medical conditions or impairments that, in the view of the investigator, would obstruct study participation * Plan to permanently relocate from the greater Boston, MA or Chapel Hill NC areas during the trial period * Planned knee or hip arthroplasty during the study period * Undergoing cancer treatment * \< 50 years old * Circulating phylloquinone ≥ 1.0 nmol/L * Warfarin (Jantoven) use * Use of other investigational drugs * Use of herbal, botanical or vitamin K supplements * Use of assistive walking devices
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Plasma uncarboxylated matrix gla protein | 24 weeks | Plasma uncarboxylated matrix gla protein is considered a functional indicator of vitamin K status. We will evaluate how it changes in response to 1 mg/d vitamin K supplementation in adults with low vitamin K status at baseline and with radiographic knee OA. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plasma phylloquinone | 24 weeks | Circulating phylloquinone is considered a global indicator of vitamin K status. We will evaluate how it changes in response to 1 mg/d vitamin K supplementation in adults with low vitamin K status at baseline and with radiographic knee OA. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Lower-extremity function - self reported | 12 and 24 weeks | The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) function index is a disease-specific, self-administered questionnaire, for assessing health status and health outcomes in osteoarthritis of the knee and/or hip. WOMAC function scores range from 0-68, with lower scores reflecting better function. |
| Lower-extremity function - objective measures | 24 weeks | 40-m fast gait speed, Chair stand test, Stair climb test, Timed-up-and-go test, 6 min walk test are measures of lower-extremity function recommended by the Osteoarthritis Research Society International to test physical performance in people with knee OA. |
| Knee pain | 12 and 24 weeks | Knee pain, which is symptomatic of OA, will be evaluated using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and the Measurement of Intermittent and Constant Osteoarthritis Pain (ICOAP) self-reported questionnaires. WOMAC pain scores range from 0-20, with higher scores reflecting more pain. ICOAP scores range from 0-100, with higher scores reflecting more pain. |
Countries
United States
Outcome results
None listed